Gene test race: can early screening unlock new cancer treatments?
NCT ID NCT06958224
Summary
This study aims to see if performing a broad genetic test on tumors early in treatment, rather than later, helps find more personalized treatment options for people with advanced pancreatic, liver, or triple-negative breast cancer. It will compare two approaches: one group gets the broad test at diagnosis, while the other gets it after their first treatment stops working. The main goal is to see which approach leads to more patients actually starting a new, targeted treatment based on their tumor's genetics.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.